TY - JOUR
T1 - Drug attrition during pre-clinical and clinical development
T2 - Understanding and managing drug-induced cardiotoxicity
AU - Ferri, Nicola
AU - Siegl, Peter
AU - Corsini, Alberto
AU - Herrmann, Joerg
AU - Lerman, Amir
AU - Benghozi, Renee
PY - 2013/6
Y1 - 2013/6
N2 - Cardiovascular toxicity remains a major cause of concern during preclinical and clinical development as well as contributing to post-approval withdrawal of medicines. This issue is particularly relevant for anticancer drugs where, the significant improvement in the life expectancies of patients has dramatically extended the use and duration of drug therapies. Nevertheless, cardiotoxicity is also observed with other classes of drugs, including antibiotics, antidepressants, and antipsychotics. This article summarizes the clinical manifestations of drug-induced cardiotoxicity by various cancer chemotherapies and novel drugs for the treatment of other diseases. Furthermore, it presents on overview of biomarker and imaging techniques for the detection of drug-induced cardiotoxicity. Guidelines for the management of patients exposed to drugs with cardiotoxic potential are presented as well as a checklist for collecting information when a safety signal is observed in clinical trials to more effectively assess the risk of cardiotoxicity and manage patient safety.
AB - Cardiovascular toxicity remains a major cause of concern during preclinical and clinical development as well as contributing to post-approval withdrawal of medicines. This issue is particularly relevant for anticancer drugs where, the significant improvement in the life expectancies of patients has dramatically extended the use and duration of drug therapies. Nevertheless, cardiotoxicity is also observed with other classes of drugs, including antibiotics, antidepressants, and antipsychotics. This article summarizes the clinical manifestations of drug-induced cardiotoxicity by various cancer chemotherapies and novel drugs for the treatment of other diseases. Furthermore, it presents on overview of biomarker and imaging techniques for the detection of drug-induced cardiotoxicity. Guidelines for the management of patients exposed to drugs with cardiotoxic potential are presented as well as a checklist for collecting information when a safety signal is observed in clinical trials to more effectively assess the risk of cardiotoxicity and manage patient safety.
KW - Drug cardiotoxicity
KW - Monitoring cardiotoxicity
KW - Patients management
UR - http://www.scopus.com/inward/record.url?scp=84877579534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877579534&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2013.03.005
DO - 10.1016/j.pharmthera.2013.03.005
M3 - Review article
C2 - 23507039
AN - SCOPUS:84877579534
SN - 0163-7258
VL - 138
SP - 470
EP - 484
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
IS - 3
ER -